Following the news that the FDA has approved GSK’s Blujepa (gepotidacin) and Innoviva’s Nuzolvence (zoliflodacin) for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents:
Fiona Chisholm, Associate Director of Infectious Diseases at GlobalData, a leading data and analytics company, offers her view:
“Blujepa and Nuzolvence are the first drugs from new antibiotic classes to be approved for the treatment of gonorrhea in over three decades. These approvals represent a significant milestone in a market that has long been characterized by a pressing unmet need for novel therapies.
“Gonorrhea, caused by the bacterium Neisseria gonorrhoeae, is one of the most prevalent sexually transmitted infections (STIs) in the US. According to GlobalData epidemiologists, there were over 848,000 diagnosed incident cases in the US in 2024, and this is expected to increase to nearly 875,500 diagnosed incident cases by 2029.
“In addition to the high incidence rate, gonorrhea is becoming increasingly challenging to treat. The spread of antimicrobial resistance (AMR) to many antibiotics previously used as first-line therapies has effectively diminished the treatment options for this infection, meaning some cases are very challenging or potentially even impossible to treat. Even in so-called uncomplicated cases, in which the infection is localized to an initial site and has not spread to the joints, blood or internal organs, antibiotic-resistance can still occur.
“Blujepa and Nuzolvence are orally administered antibiotics with novel mechanisms of action. In Phase III trials in patients with uncomplicated gonorrhea, both drugs demonstrated non-inferiority to intramuscular ceftriaxone combined with oral azithromycin, the standard of care combination therapy, in terms of microbiological cure rates. These therapies therefore provide new orally administered options for patients currently relying on injectable treatments. This offers patients greater convenience and has potential to reduce the burden of gonorrhea in hospitals and other healthcare settings such as sexual health clinics.
“Blujepa is already available in the US, having received FDA approval for the treatment of uncomplicated urinary tract infections in females in March 2025. This may confer a competitive advantage over Nuzolvence in terms of physicians having greater familiarity with this drug. However, Nuzolvence has the advantage of greater ease of use and convenience. It is administered as granules dissolved in water in a single dose, whereas Blujepa is administered as two oral tablets, taken approximately 12 hours apart. Blujepa also has a narrower label than Nuzolvence, as it is only indicated for patients with limited or no alternative treatment options.
“According to GlobalData’s drugs database, there are no other assets in late-stage development for gonorrhea, an indication of R&D underinvestment.
“Nonetheless, the upcoming market entry of Blujepa, and Nuzolvence, in the near future represents an exciting new era in this space and addresses a key unmet need for orally administered antibiotics with novel mechanisms of action.”
